• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Asensus Surgical Announces Closing of Acquisition by KARL STORZ

    8/22/24 8:58:30 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care
    Get the next $ASXC alert in real time by email

    RESEARCH TRIANGLE PARK, N.C. and TUTTLINGEN, Germany, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC) ("Asensus Surgical" or "Asensus"), a global leader of innovative digital solutions for the operating room, today announced the closing of the merger (the "Merger") with the KARL STORZ Group ("KARL STORZ"). The transaction was completed following approval by the Asensus Surgical stockholders.

    Under the terms of the merger agreement, KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ, has acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash. As a result of the acquisition, Asensus Surgical has become a subsidiary of KARL STORZ and its common stock has ceased trading on the NYSE American Exchange.

    "We are thrilled to complete this merger with KARL STORZ, which marks an exciting new chapter for Asensus," said Anthony Fernando, Asensus Surgical President and CEO. "By joining forces with a leading company in endoscopy that became a system provider for integrated MedTech, we are well-positioned to accelerate the development and delivery of our innovative robotic and digital surgical solutions. This union will benefit patients and surgeons worldwide by advancing precise, safer, and more predictable surgical outcomes."

    The closing of this acquisition is a significant milestone for both companies.

    "Asensus' cutting-edge technology and expertise in robotic surgery complements our comprehensive portfolio of surgical solutions," said Karl-Christian Storz, CEO of KARL STORZ. "This enhances our portfolio and market presence, strengthening our position in the growing robotic and digital surgical market, particularly with the development of the next generation LUNA™ system. We are thrilled to welcome 200-plus talented Asensus team members into our company. Together, we will revolutionize healthcare by delivering better outcomes for patients and surgical teams worldwide."

    Asensus was identified for acquisition by KARL STORZ for two primary reasons: the organization's talent and technology. As a potential partner, Asensus turned out to be a perfect fit due to its similar philosophy and vision, and its experience in bringing its first-generation Senhance robot to market. Its second-generation LUNA™ System is also positioned to offer enhanced robotic precision, greater dexterity and a superior range of motion manipulation, which complements KARL STORZ's advanced visualization capabilities.

    LUNA™ is currently under development and has not been submitted to, or cleared by, the US FDA or other global regulators, and is not available for sale in any market. Jefferies LLC served as financial advisor to Asensus Surgical, and Ballard Spahr LLP served as legal counsel to Asensus Surgical. UBS Investment Bank served as financial advisor to KARL STORZ, and Ropes & Gray LLP served as legal counsel to KARL STORZ.

    About Asensus Surgical, Inc.

    Asensus Surgical is revolutionizing surgery with the first intra-operative Augmented Intelligence technology approved for use in operating rooms around the world. Recognized as an award-winning leader in digital technology, Asensus is committed to making surgery more accessible and predictable while delivering consistently superior outcomes. Asensus' novel approach to digitizing laparoscopy has led to system placements globally. Led by engineers, medical professionals, and industry luminaries, Asensus is powered by human ingenuity and driven by collaboration. To learn more about the Senhance® Surgical System and the new LUNA™ System in development, visit www.asensus.com.

    About KARL STORZ SE & Co. KG

    The medical technology company KARL STORZ was founded in 1945 in Tuttlingen, Germany, and is an international leader in the world of endoscopy. Now in its third generation, the family-owned company employs 9,400 people in more than 40 countries worldwide. The company portfolio includes 13,000 products for human and veterinary medicine. KARL STORZ stands for visionary design, precision craftsmanship and clinical effectiveness. Sales in the 2023 financial year amounted to 2.17 billion euros. Production sites are located in Germany, the USA, Switzerland and Estonia. KARL STORZ Endoscopy-America is a subsidiary of KARL STORZ SE & Co. KG.

    Caution Regarding Forward Looking Statements

    This communication includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include statements concerning anticipated future events and expectations that are not historical facts. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Actual results may vary materially from those expressed or implied by the forward-looking statements herein due to risks and uncertainties. These risks and uncertainties include, but are not limited to, those associated with the future development and commercial success of Asensus' robotic and digital surgical solutions.

    KARL STORZ MEDIA CONTACT:

    Anja Ebert

    Senior Director Corporate Communications

    KARL STORZ SE & Co. KG                                                                                         

    [email protected]

    +49 162 2800649

    ASENSUS SURGICAL CONTACT:

    INVESTORS                                                                                                                                   

    Mark Klausner or Mike Vallie

    ICR Westwicke

    [email protected]

    443-213-0499

    MEDIA    

    Dan Ventresca

    Matter Communications

    [email protected]

    617-874-5488



    Primary Logo

    Get the next $ASXC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ASXC

    DatePrice TargetRatingAnalyst
    11/16/2023Overweight → Neutral
    Cantor Fitzgerald
    9/8/2022$1.50Overweight
    Cantor Fitzgerald
    9/8/2022$1.50Buy
    Stifel
    More analyst ratings

    $ASXC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Asensus Surgical Announces Closing of Acquisition by KARL STORZ

      RESEARCH TRIANGLE PARK, N.C. and TUTTLINGEN, Germany, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC) ("Asensus Surgical" or "Asensus"), a global leader of innovative digital solutions for the operating room, today announced the closing of the merger (the "Merger") with the KARL STORZ Group ("KARL STORZ"). The transaction was completed following approval by the Asensus Surgical stockholders. Under the terms of the merger agreement, KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ, has acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash. As a result of the acquisition, Asensus Surgical has become a sub

      8/22/24 8:58:30 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Asensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2024

      RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial results for the second quarter 2024. Recent Highlights Announced a definitive merger agreement (the "Merger Agreement") with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"), a wholly owned direct subsidiary of KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company. Under the Merger Agreement, KARL STORZ will acquire all of the outstanding shares of Asensus Surgical for $0.35 per share in cash (the "Merger")Leading independent proxy advisory firms,

      8/13/24 4:05:00 PM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 13, 2024

      RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-717-1738 for domesticcallers and 1-646-307-1865 for international callers, approximately

      8/8/24 6:50:00 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Asensus Surgical downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Asensus Surgical from Overweight to Neutral

      11/16/23 7:11:26 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Asensus Surgical with a new price target

      Cantor Fitzgerald initiated coverage of Asensus Surgical with a rating of Overweight and set a new price target of $1.50

      9/8/22 7:20:54 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Asensus Surgical with a new price target

      Stifel initiated coverage of Asensus Surgical with a rating of Buy and set a new price target of $1.50

      9/8/22 7:19:37 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    Leadership Updates

    Live Leadership Updates

    See more
    • Asensus Surgical Announces the Appointment of Two New Board Members

      Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing two new board members, Elizabeth Kwo, MD and Kevin Hobert, effective immediately. "We are delighted to welcome two accomplished industry veterans to our Board of Directors, each of whom bring highly relevant and unique skills to the organization that complement our current leadership team in an impactful way," said Paul LaViolette, Chairman of the Board of Asensus Surgical. "Liz has a tremendous track record of bringing innovative healthcare t

      7/26/21 6:55:00 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox

      BOTHELL, Wash., May 28, 2021 (GLOBE NEWSWIRE) -- With great sadness, Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company") announces that Gary Wilcox, Ph.D., Chairman, CEO and co-founder, suddenly passed away Wednesday, May 26 at the age of 74. The Board of Directors and staff of Cocrystal extend their deepest condolences to the Wilcox family and express their gratitude for Gary's contributions to Cocrystal and to human health. The Cocrystal Board of Directors has designated Sam Lee, Ph.D., President, and James Martin, CFO, to share the CEO responsibilities while seeking a successor for the position. Roger Kornberg, Ph.D., Cocrystal co-founder, Chief Scientist, Director and

      5/28/21 8:00:00 AM ET
      $OPK
      $ASXC
      $GPX
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Other Consumer Services

    $ASXC
    Financials

    Live finance-specific insights

    See more
    • Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 13, 2024

      RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-717-1738 for domesticcallers and 1-646-307-1865 for international callers, approximately

      8/8/24 6:50:00 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 14, 2024

      RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To access the live audi

      5/7/24 6:55:00 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Asensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024

      RESEARCH TRIANGLE PARK, N.C., March 15, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, March 21, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To

      3/15/24 6:55:00 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Asensus Surgical Inc.

      SC 13G - ASENSUS SURGICAL, INC. (0000876378) (Subject)

      7/15/24 5:33:42 PM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Asensus Surgical Inc. (Amendment)

      SC 13G/A - ASENSUS SURGICAL, INC. (0000876378) (Subject)

      1/20/23 9:38:51 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Asensus Surgical Inc.

      SC 13G - ASENSUS SURGICAL, INC. (0000876378) (Subject)

      2/10/22 12:45:15 PM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Starling William N Jr bought $5,078 worth of shares (18,134 units at $0.28) and sold $5,078 worth of shares (18,134 units at $0.28) (SEC Form 4)

      4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

      12/18/23 6:26:08 PM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Asensus Surgical Inc.

      15-12G - ASENSUS SURGICAL, INC. (0000876378) (Filer)

      9/3/24 7:00:04 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Asensus Surgical Inc.

      EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)

      8/27/24 12:15:07 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Asensus Surgical Inc.

      EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)

      8/27/24 12:15:04 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kwo Elizabeth returned 117,201 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

      8/22/24 9:13:46 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Director Hobert Kevin J returned 54,201 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

      8/22/24 9:12:57 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Director Pfenniger Richard C Jr returned 189,417 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

      8/22/24 9:12:10 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care